- 01You test Lp(a) once and cannot move it; it tells you how hard to push the numbers you can move
Lp(a) is set by your genes and barely shifts with diet or exercise, and a high result does not on its own diagnose heart disease. A normal LDL does not cancel it, because apo(a) adds harm of its own. What you can change is everything that stacks on top: LDL, blood pressure, smoking and blood sugar. A high Lp(a) is the reason to manage those harder and earlier.
A high lipoprotein(a) result reads like an alarm, but the number tells you about a lifelong tendency; on its own it does not show whether you have heart or valve disease today. Lp(a), said "L-P-little-a", is a cholesterol-carrying particle whose level is set mostly by one gene, so a high result usually stays high for life. You test it once and cannot move it much; what it tells you is how hard to push the numbers you can move: LDL, blood pressure, smoking and blood sugar.
The marker this page is about
Is my Lp(a) high? The cutoffs in mg/dL and nmol/L
The European Atherosclerosis Society (EAS) uses three bands: under 30 mg/dL (under 75 nmol/L) makes Lp(a)-related risk unlikely, 30 to 50 mg/dL (75 to 125 nmol/L) is a gray zone, and over 50 mg/dL (over 125 nmol/L) is high 1. The American Heart Association and American College of Cardiology use the same line in their 2018 cholesterol guideline, where high Lp(a) counts as a risk enhancer: a factor that tips a borderline case toward treatment 2.
An Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a).Grundy SM et al., 2018 AHA/ACC Guideline on the Management of Blood Cholesterol 2
Where an example Lp(a) of 160 nmol/L fallsnmol/L
| Band | mg/dL | nmol/L | What it means |
|---|---|---|---|
| Low (normal) | Under 30 | Under 75 | Lp(a)-related risk unlikely |
| Gray zone | 30 to 50 | 75 to 125 | Weighs in only alongside other risk factors |
| High | Over 50 | Over 125 | A risk enhancer in US and European guidelines |
| Very high | Over 180 | Over 430 | Lifetime risk similar to familial hypercholesterolemia (inherited very high LDL) |
Under 30 mg/dL (under 75 nmol/L) is the usual normal range. In the gray zone? Mention it to your doctor alongside your LDL, blood pressure and family history; it tips the balance only if those are borderline.
Check which unit your lab used before you compare your number with any chart. Lp(a) cannot be converted between mg/dL and nmol/L with one fixed factor, because the apo(a) protein on each particle comes in different sizes from person to person, and a mass unit (mg/dL) counts a large particle differently from a small one 1. The EAS prefers nmol/L, which counts particles. Multiplying mg/dL by about 2 to 2.5 gives only a rough idea. For units on other tests, see the lab units guide.
Read your Lp(a), in the right unit
mg/dL and nmol/L are not the same scale. Enter your value with its unit. Nothing leaves your browser.

Why Lp(a) runs high
Your Lp(a) level is set mainly by the LPA gene, which explains roughly 70% to over 90% of the difference between people 1. The gene builds apo(a), a protein whose size varies from person to person. People born with a smaller apo(a) usually make more Lp(a), so their level runs higher. Lp(a) reaches its adult level in early childhood and then stays fairly flat for life 1.
About 1 in 5 people have Lp(a) above 50 mg/dL 1. Typical levels differ by ancestry: in UK Biobank, Black participants had the highest median Lp(a) and South Asian participants also ran higher than white participants, while each extra 50 nmol/L carried a similar added risk across groups 3.
A few conditions push Lp(a) up on top of genes, and one pulls it down 1:
- Menopause: Lp(a) often rises as estrogen falls.
- Chronic kidney disease, and nephrotic syndrome (kidneys leaking large amounts of protein into urine).
- Hypothyroidism (an underactive thyroid).
- Pregnancy, temporarily.
- Liver disease lowers Lp(a), because the liver makes it; a falling Lp(a) is no sign of better heart health in that setting.
Does high Lp(a) cause symptoms?
High Lp(a) causes no symptoms of its own. When symptoms appear, they come from the diseases Lp(a) feeds over years: narrowed heart arteries, stroke, narrowed leg arteries and a stiff aortic valve.
Some history makes high Lp(a) more likely, and these are the usual reasons a doctor orders the test:
- A heart attack or stroke in you before 55 (men) or 65 (women), or in a parent, brother or sister at those ages.
- Heart disease even though your LDL has always looked normal.
- Aortic stenosis (a narrowed aortic valve), especially at a younger age.
- Familial hypercholesterolemia, the inherited form of very high LDL.
- A relative already known to have high Lp(a).
How much risk does high Lp(a) add, and does it affect life expectancy?
Lp(a) risk rises in a steady line with no level that flips from safe to dangerous. In 460,506 UK Biobank participants, each extra 50 nmol/L of Lp(a) went with about 11% higher risk of atherosclerotic cardiovascular disease (heart attack, stroke and artery disease) 3. So an Lp(a) of 250 nmol/L carries more risk than an Lp(a) of 130 nmol/L, though both sit in the high band.
At the top end, the effect is larger. The Copenhagen studies found that people in roughly the top 5% for Lp(a) had about two to three times the heart attack risk of people with the lowest levels 1. People born with Lp(a)-raising gene variants had raised heart attack risk too, which is strong evidence that Lp(a) itself causes the harm 4. Variants in the LPA gene are also tied to calcium build-up in the aortic valve and to aortic stenosis 5.
For life expectancy, the best data come from the Copenhagen General Population Study. People with Lp(a) above about 93 mg/dL (199 nmol/L) had about 20% higher all-cause mortality and 50% higher cardiovascular mortality than people with the lowest levels 6. That is a real increase and a modest one. Many people with high Lp(a) never have a heart attack, and the outcome depends heavily on the risks you can change: LDL, blood pressure, smoking and diabetes.
Lp(a), LDL and ApoB: how they fit together
An Lp(a) particle is an LDL particle with an extra protein, apo(a), clipped onto it. Like every LDL particle, it carries one apolipoprotein B (ApoB) molecule, so Lp(a) particles are counted inside an ApoB result. The cholesterol inside Lp(a) is also counted inside the LDL number on a standard lipid panel, which is one reason Lp(a) has to be ordered as its own test.
A normal LDL does not cancel a high Lp(a), because the apo(a) part adds harm that LDL particles lack: it carries oxidized phospholipids (fats that drive inflammation in artery walls and valve calcification) and it nudges blood toward clotting. When high LDL and high Lp(a) occur together, the risks stack. For why particle counts often track risk better than cholesterol mass, see ApoB vs LDL.
Read these beside your Lp(a)
Can you lower lipoprotein(a)?
Lifestyle barely moves Lp(a). Diet, exercise, weight loss and omega-3 supplements have little or no effect on the number 1, though the same habits still lower heart risk through LDL, blood pressure and blood sugar. Medicines differ: some lower Lp(a) and have proven fewer heart events, some lower it with no proven benefit, and the most powerful are still in trials.
| Approach | Effect on Lp(a) | Proven to cut heart events? |
|---|---|---|
| Diet, exercise, weight loss, omega-3 | Little or none | Yes for overall risk, through other markers |
| Statins | No fall; often a small rise | Yes, the backbone of treatment |
| PCSK9 inhibitors (evolocumab, alirocumab) | Down about 25 to 30% | Yes; bigger absolute benefit with higher Lp(a) |
| Niacin | Down | No; more side effects in outcome trials |
| Lipoprotein apheresis | Down sharply after each session, then climbs back | Used for very high Lp(a) with established artery disease |
| Pelacarsen, olpasiran, lepodisiran (trial drugs) | Down about 80% to over 95% | Outcome trials under way or just reporting; not yet routine care |
Statins can raise Lp(a): a meta-analysis found average increases of roughly 9% to 20% on statin therapy 7. They still lower heart attack and stroke risk by cutting LDL, so guidelines do not treat a rise in Lp(a) on a statin as a reason to stop it. Any change to a medicine is a decision to make with your doctor.
PCSK9 inhibitors are injected drugs that help the liver clear LDL. In the FOURIER trial, the PCSK9 inhibitor evolocumab lowered Lp(a) by a median of 27%, and people who started with higher Lp(a) gained more absolute benefit 8. Niacin lowers Lp(a), but adding it to a statin did not reduce major heart events and caused more side effects 9.
Lipoprotein apheresis filters Lp(a) and LDL out of the blood every one to two weeks. In the US it is cleared for people with Lp(a) of 60 mg/dL or more, LDL that stays at 100 mg/dL or more despite treatment, and established heart or leg artery disease. Newer drugs aimed at Lp(a) itself silence the LPA gene's message: pelacarsen cut Lp(a) by up to about 80% in a dose-ranging trial 10, and olpasiran by more than 95% 11; lepodisiran works the same way. Large outcome trials will show whether those cuts prevent heart attacks; none of these drugs is yet routine care, so ask your doctor about their current status.
The medicine that carries the evidence
What to do with a high Lp(a) result
- 1Look hard at your LDL and ApoBLDL is the main lever. US guidelines treat high Lp(a) as a reason to favor starting a statin in borderline cases 2, and European guidance supports aiming for a lower LDL 1; your doctor sets the target. If your cholesterol is high as well, the high cholesterol guide covers that side.
- 2Get the other risks in orderBlood pressure, smoking, blood sugar and weight all add to Lp(a) risk. hs-CRP (high-sensitivity C-reactive protein, a marker of low-grade inflammation) gives context on artery inflammation.
- 3Ask about a coronary calcium scoreYour doctor can estimate your 10-year risk (the chance of a heart attack or stroke in the next 10 years) from your age, blood pressure, cholesterol and smoking. When that risk is borderline, a calcium scan (a quick, low-dose CT of the heart) can show whether plaque has already formed. Aspirin is a decision for your doctor, since it raises bleeding risk.
- 4Tell your familyParents, brothers, sisters and children each have about a 50% chance of sharing a high Lp(a). The EAS supports testing them, called cascade testing 1.
- 5Know when to see a specialistAsk for a cardiologist or lipid clinic if your Lp(a) is above 180 mg/dL (430 nmol/L), you or a close relative had early heart disease, you have aortic stenosis, or you have familial hypercholesterolemia.
CalculatorLDL calculatorYour LDL is the number you can move. Work it out from your panel with the newer equation.Work it out Who should test, and do you need to retest Lp(a)?
The EAS advises measuring Lp(a) at least once in every adult, and especially in people with early heart disease in themselves or the family, familial hypercholesterolemia, aortic stenosis or a relative with high Lp(a) 1. One test is usually enough for life, because the level barely changes after childhood 1. A repeat makes sense if:
- Your first result was in the gray zone.
- It was drawn while you were ill or pregnant.
- You have since gone through menopause.
- Your kidney or thyroid function has changed.
- You start a drug aimed at Lp(a).
Use the same lab and unit so the two numbers compare. The test is a single blood draw, no fasting needed, and is usually inexpensive, but it is left out of standard cholesterol panels, so you have to ask for it by name.
Citations
- Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925-3946.
- Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 2019;139:e1082-e1143.
- Patel AP et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021;41:465-474.
- Kamstrup PR et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-2339.
- Thanassoulis G et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503-512.
- Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J 2019;40:2760-2770.
- Tsimikas S et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020;41:2275-2284.
- O'Donoghue ML et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation 2019;139:1483-1492.
- HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-212.
- Tsimikas S et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020;382:244-255.
- O'Donoghue ML et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022;387:1855-1864.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.



